You are here

Home » Content

Serum Neopterin Levels in Obese and Nonobese Patients with Obstructive Sleep Apnea Syndrome

Obstrüktif Sleep Apneli Obez ve Obez Olmayan Hastalarda Serum Neopterin Seviyeleri

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objective: Obstructive sleep apnea syndrome (OSAS) is one of the most common sleep breathing disorder characterized by nocturnal oxygen desaturation and repeated upper airway obstruction episodes during sleep. Neopterin (NP), as an immune modulator, is secreted by macrophages activated by T-lymphocytes. In the light of literature, higher serum NP levels are reported to be encountered in obese subjects. While this marker was used in obese OSAS subjects, no data related to this marker to be used in non-obese OSAS subjects could be encountered in previous studies. In this study, it was aimed to compare serum NP levels in non-obese with obese OSAS subjects. Methods: Twenty non-obese OSAS, 15 obese OSAS were enrolled into this study. Diagnostic polysomnography (PSG) was performed in all patients during all night sleep. Sleep stages and respiratory events were manually scored. Serum NP levels of obese OSAS subjects were compared with non-obese OSAS subjects . Results: Serum neopterin levels were 5.25±0.43 ng/ml in obese and 5.17±0.52 ng/ml in non-obese OSAS patients (p > 0.05). Conclusion: In this study, no significant difference was found in terms of NP levels between non-obese and obese OSAS patients.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Obstruktif sleep apne sendromu (OSAS) uyku oksijen saturasyonun bozulması ve uyku sırasında tekrarlayan üst hava yolu obstruksiyonu epizodları ile karakterize en yaygın uyku solunum bozukluğudur. Bir immünomodülatör olan neopterin (NP) T lenfositler tarafından aktive edilen makrofajlar tarafından salgılanmaktadır. Literatür ışığında, yüksek serum NP seviyelerinin obes kişilerde rastlandığı rapor edilmiştir. Bu marker obez OSAS’lı kişilerde kullanılırken, obez olmayan OSAS’lı kişilerde bu markerin kullanıldığıyla ilişkili bilgilere önceki çalışmalarda rastlanılmadı. Bu çalışmada biz, obez OSAS’lı kişilerle obez olmayan OSAS’lı kişiler arasında serum NP seviyelerini karşılaştırmayı amaçladık. Metod: Bu çalışmaya 20 obez olmayan ve 15 obez OSAS’lı hasta dahil edildi. Hastalara bir gece boyunca diagnostik polisomnografi (PGS) uygulandı. Uyku süreçleri ve respiratuar durumlar manuel olarak skorlandı. Obez OSAS’lıların serum NP düzeyleri non-obez OSAS’lılarla karşılaştırıldı. Bulgular: Serum neopterin seviyeleri obez OSAS’lılarda 5.25±0.43 ng/ml, obez olmayan OSAS’lılarda 5.17±0.52 ng/ml olarak bulundu (p > 0.05). Sonuç: Bu çalışmada, obez ve obes olmayan OSAS’lı hastalar arasında NP seviyeleri açısından önemli bir farklılık bulunamamıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-serum-neopterin-levels-obese-and-nonobese-patients-obstructive-sleep-apnea-syndrome.pdf
  • 3
165-168
  • Turkish

REFERENCES

References: 

1. Phillipson EA. Sleep apnea, in Braunwald E, Fauci AS, Kasper
DL, Hauser SL, Longo DL, Jameson JL (eds): Harrison’s
Principles of Internal Medicine, 15th ed. New York, McGraw-
Hill 2001; 1520-3.
2. Partinen M, Jamieson A, Guilleminault C. Long–term outcome
for obstructive sleep apnea syndrome patients: mortality. Chest
1988; 94:1200-4.
3. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of
the association between sleep-disordered breathing and
hypertension. N Engl J Med 2000; 342: 1378-84.
4. Shepard JW. Hypertansion, cardiac arrytmias, myocardial
infarction, and stroke in relation to obsructive sleep apnea. Clin
Chest Med 1992; 13:437-58.
5. Wolk R, Kara T, Somers VK. Sleep–disorderd breathing and
cardiovasculer diseases. Circulation 2003; 108: 9-12.
Table 1. Clinical and polisomnographic characteristics of study group
OSA(+)
Obese (a) Non-Obese (b) p value
Serum neopterin 5.3±0.4 5.2±0.5 >0.05
Age 46.1±9.4 43.7±7.1 >0.05
BMI (kg/m2) 32.9±1.9 26.1 ± 3.7
ESS 7.0 ±5.8 7.1 ±3.7 >0.05
Total sleep time(h) 379.2±336.6 361.6 ±67.5 >0.05
Sleep efficacy (%) 81.9±7.9 78.7±12.6 >0.05
Stage 1-2 (%) 81.4±18.9 79.6±13.4 >0.05
Stage3 (%) 17.5±18.1 17.2±11.4 >0.05
REM (%) 0.8±1.6 2.5±3.8 >0.05
AI (per h) 37.7±35.6 16.3 ±14.8 <0.05
AHI(per h) 60.6± 31.3 36.3±18.3 <0.05
Min SO2 35.9±37.5 40.4± 41.5 >0.05
Arousal index 29.2±27.1 23.6±17.1 >0.05
BMI: Body mass index, ESS: Epworth sleepiness scale, AHI: Apnea-Hypopnea
index, AI: Apnea index, REM: Rapid eye movement.
Bekci et al.
168
6. Silverberg DS, Oksenberg A. Are sleep related breathing
disorders important contributing factors to the production of
essential hypertansion? Curr Hypertens Rep 2001; 3: 209-15.
7. Zwillich C, Sinoway L. Surges of muscle sympathetic nerve
activity during obstructive apnea are linked to hypoxemia. J Appl
Physiol 1995; 79: 581-88.
8. Jelic S, Bartels MN, Mateika JH, Ngai P, DeMeersman RE,
Basner RC. Arterial stiffness increases during obstructive sleep
apneas. Sleep 2002; 25: 15-20.
9. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A,
Reibnegger G, Schmidt K, Weiss G, Wachter H. Pteridine
biosynthesis in human endothelial cells: Impact on nitric oxidemediated
formation of cyclic GMP. J Biol Chem 1993; 268:
1842-6.
10. Punjabi NM, Beamer BA, Jain A, Spencer ME, Fedarko N.
Elevated levels of neopterin in sleep-disordered breathing. Chest
2007;132:1124-30.
11. Ursavaş A, Karadag M, Oral AY, Demirdogen E, Oral HB, Ege
E. Association between serum neopterin, obesity and daytime
sleepiness in patients with obstructive sleep apnea. Respir Med
2008;102:1193-7.
12. Ledochowski M, Murr C, Widner B, Fuchs D. Association
between insulin resistance, body mass and neopterin
concentrations. Clin Chim Acta 1999;282:115-23.
13. Thorpy M, Committee ftDCS. The International Classification of
Sleep Disorders: Diagnostic and Coding Manuel. Rochester MN,
American Sleep Disorders Association, 1990
14. Tracy RP. Is visceral adiposity the enemy within? Arterioscler
Thromb Vasc Biol 2001; 21: 881-3.
15. Kern PA, Saghizadeh M, Ong JM, Bosh RJ, Deem R, Simsolo
RB. The expression of tumor necrosis factor in human adipose
tissue. Regulation by obesity, weight loss, and relationship to
lipoprotein lipase. J Clin Invest 1995; 95:2111-9.
16. Avanzas, -p Arroyo-Espliguero, Quiles, J Roy D, Kaski. Elevated
serum neopterin predicts future adverse cardiac events in patients
with chronic stable angina pectoris, Eur Heart 2005;26:457-63
17. Gupta S, Frederics S, Schwartzman RA, Holt DW, Kaski JC.
Serum neopterin in acute coronary syndromes. Lancet 1997; 349:
1252-3.
18. Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H,
Klein W. Neopterin levels in patients with coronary artery
diseases. Atherosclerosis 1992; 94: 87-88.
19. Erten Y, Ozturk M.A, Oktar S, Pasaoglu H, Reis K.A, Derici U.
Association between neopterin and carotid intima-media
thickness in hemodialysis patients. Nephron Clin Pract
2005;101:134-8.
20. Bozdemir AE, Barutcuoglu B, Dereli D, Kabaroglu C, Habif S,
Bayindir O. C-reactive protein and neopterin levels in healthy
non-obese adults. Clin Chem Lab Med 2006;44:317-21.

Thank you for copying data from http://www.arastirmax.com